Procainamide Hydrochloride Injection

[04 June 2014]

Products Affected - Description

Procainamide injection, Hospira

Reason for the Shortage

  • Hospira had procainamide injection on shortage due to manufacturing delays.
  • There are no other manufacturers of procainamide injection.

Available Products

Procainamide injection, Hospira
100 mg/mL, 10 mL vials (NDC 00409-1902-01)
500 mg/mL, 2 mL vials (NDC 00409-1903-01)

Estimated Resupply Dates

Hospira has procainamide 100 mg/mL 10 mL vials and 500 mg/mL 2 mL vials available.


Both vial sizes provide procainamide 1 gram, although the concentration is different. Ensure safe use of different concentrations during this shortage.

Related Shortages


June 4, 2014; May 9, 2014; April 25, 2014; March 13, 2014; January 17, 2014; October 18, 2013; October 3, 2013; September 23, 2013; August 29, 2013; August 12, 2013; August 6, 2013; July 3, 2013; June 10, 2013; May 30, 2013; April 25, 2013; March 25, 2013; February 27, 2013; January 21, 2013; December 31, 2012; December 26, 2012; December 10, 2012; October 19, 2012; September 5, 2012; July 25, 2012; June 18, 2012; May 14, 2012; April 11, 2012; March 13, 2012; January 3, 2012; November 28, 2011, University of Utah, Drug Information Service. Copyright 2014, Drug Information Service, University of Utah, Salt Lake City, UT.


This information is provided through the support of Novation to ASHP solely as a service to its members, which shall not use this information for their further commercial use. The content was prepared by the Drug Information Center of University of Utah. Novation, ASHP, and the University of Utah make no representations or warranties, express or implied, including, but not limited to, any implied warranty of merchantability and/or fitness for a particular purpose, which respect to such information, and specifically disclaim all such warranties. Users of this information are advised that decisions regarding the use of drugs and drug therapies are complex medical decisions and that in using this information, each user must exercise his or her own independent professional judgment. Neither Novation, ASHP nor the University of Utah assumes any liability for persons administering or receiving drugs or other medical care in reliance upon this information, or otherwise in connection with this bulletin. Neither Novation, ASHP nor University of Utah endorses or recommends the use of any drug.

« Back to Drug Shortage Product Bulletins

Advocacy Activity
Get the latest updates on ASHP's advocacy activity on drug shortages.